CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
Sponsor: pharmaand GmbH
This PHASE3 trial investigates Epithelial Ovarian Cancer and Fallopian Tube Cancer and is currently completed. pharmaand GmbH leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jun 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Sep 2023 — Oct 2023 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Jul 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2023 — Jul 2023 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2022 — Mar 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- pharmaand GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangel'sk, Russia , Bialystok, Poland , Bologna, Italy , Candiolo, Italy , Haifa, Israel , Kfar Saba, Israel , London, Canada , London, United Kingdom , Middlesex, United Kingdom , Milan, Italy and 15 more locations